Bailey Health Solutions describes women's hormone treatment through its St. Augustine, Florida office. A nearby reader may want to investigate that in-person route. The public description leaves several details for the appointment, particularly the full prescription identity, fee schedule and continuing-care agreement.

We examined the women's hormone, office and in-office testing pages at baileyhealthsolutions.com on October 13, 2026. This is a review of the Florida practice's published information, without a clinic visit, purchased treatment or independent clinical audit.

Editorial illustration of a clinic conversation and a written care plan.
Original editorial illustration.

Settle the location before the clinical agenda

The office is listed at 224 Southpark Circle East, St. Augustine. Confirm where the appointment will take place and who will conduct it. The checked material does not establish national telehealth access or participation in a specific insurance network, so those arrangements remain questions rather than assumed benefits.

Think about the practical requirements of returning to the office for examination, testing or a procedure. A location that works for one appointment may be harder for continuing care. The appointment-preparation guide can help separate travel and administrative questions from the health concerns you want assessed.

Ask what the assessment is designed to decide

Bailey's women's page describes consultation, laboratory work, a customized plan and monitoring. Its blood-testing page describes an in-office service. Neither page determines which tests you need, whether previous results would be useful or what additional evaluation might be necessary before treatment could be considered.

Ask how the clinician will distinguish the possible explanations for your concerns. Bring observations and relevant records without turning them into a self-diagnosis. The result of an assessment may be more information, a referral or another approach; booking hormone-related care does not establish that a hormone prescription is appropriate.

Request a name beyond the treatment route

The public hormone material discusses pellets and injections. It does not supply a complete named estrogen or oral progesterone menu, so we cannot confirm an oral micronized product or identify the finished medicine a patient would receive. Ask for the ingredients, route, dispensing pharmacy and the reason for that selection.

If the medicine is compounded, ask how that affects the evidence and why it is being proposed. FDA explains that compounds are not FDA-approved and do not undergo its usual premarket assessment. Natural or bioidentical terminology does not establish a particular preparation's safety, effectiveness or quality.

Make the procedure and review plan explicit

A proposed pellet insertion should come with information about the procedure, possible complications and the plan for unwanted effects. An injection plan should identify who administers it and provides instructions. Those details cannot be reconstructed from a treatment-category heading on a public website.

Ask what improvement would count as useful and when the clinician would reassess. ACOG describes menopausal hormone choices in relation to symptoms, risks and history. Systemic estrogen and local vaginal treatment have different purposes, and appropriate uterine protection requires discussion when systemic estrogen is proposed for a person with a uterus.

Put unknown charges into the visit notes

The reviewed women's hormone and office pages did not provide a usable public schedule for consultation, testing, prescriptions and procedures. We therefore do not assign a starting price or infer that insurance will cover the service. Missing prices limit comparison without proving that care is expensive or inexpensive.

Request the amount due at the initial visit and a separate estimate for continuing treatment. Identify outside laboratory or pharmacy bills, renewal timing and cancellation conditions. A useful written quote should also explain what happens financially if assessment leads away from treatment or a later clinical decision changes the plan.

End with a clear route back to the care team

Before deciding, ask who handles concerns between appointments, how results are communicated and how records can be shared with another clinician. This review has not measured scheduling or response time. Continuing access should be an identifiable responsibility rather than an assumption based on the phrase ongoing monitoring.

Our AquaVitality note offers a regional-clinic comparison with published prices, including a discrepancy that needs confirmation. Bailey's local service may be relevant to your search, but the public information is not enough for an outcome ranking or a complete cost comparison. Carry the unanswered questions into a private clinical discussion.

Sources for this story

Public pages are a dated snapshot. A provider page supports its published description, not a clinical outcome or a completed service audit.